-
Evidence-based updates in primary care medicine By Louis Kuritzky, MD
-
In a single institutional study (M.D. Anderson), 60 older patients with chronic lymphocytic leukemia were treated with lenalidomide. Thirty-five of the 60 patients had a response lasting > 36 months, and compared with those who did not have such a durable response, those who did had lower pretreatment ß-2 microglobulin levels and were more likely to have favorable cytogenetics. Lenalidomide treatment was associated with improvement in circulating immunoglobulin levels and T-lymphocyte numbers.
-
Zolpidem and risk of falls; AVR and anticoagulation; statins in cancer patients; and FDA actions.
-
-
LAP2 was a randomized, Phase 3 trial to evaluate and compare the modality of surgical staging (laparoscopy vs laparotomy) in endometrial cancer.
-
Early pivotal trials demonstrating the efficacy of sorafenib for patients with advanced hepatocellular cancer included primarily those with minimal liver dysfunction (Child-Pugh [CP] class A).
-
In a six-site Italian retrospective analysis, treatment of elderly patients with metastatic renal cell carcinoma with sunitinib was shown to be effective but associated with significant toxicity. Although only applied to a subset, pretreatment comprehensive geriatric assessment did not offer predictive value with regard to severe toxicity or efficacy.
-
Denosumab is more effective than zoledronic acid at preventing pain in women with advanced breast cancer and bone metastases.
-
In this Phase 2 trial, 105 older patients with acute myeloid leukemia who were either treatment-naïve or at first relapse were treated with one of three schedules of oral sapacitabine: 200 mg twice daily for 7 days (group A), 300 mg twice daily for 7 days (group B), or 400 mg twice daily for 3 days each week for 2 weeks (group C).
-